Influence of the 5-HT2C receptor antagonist SB242,084 on behaviour produced by the 5-HT2 agonist Ro60-0175 and the indirect 5-HT agonist dexfenfluramine

被引:43
作者
Higgins, GA [1 ]
Ouagazzal, AM [1 ]
Grottick, AJ [1 ]
机构
[1] F Hoffmann La Roche & Co Ltd, PRBNB, CH-4070 Basel, Switzerland
关键词
Ro60-0175; SB242,084; MDL100,907; SB215,505; dexfenfluramine; 5-HT syndrome; 5-HT2C; 5-HT2A;
D O I
10.1038/sj.bjp.0704082
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
1 Ro60-0175 has been described as a selective agonist at the 5-HT2C receptor, yet it has only 10-fold higher affinity at the 5-HT2C compared to the 5-HT2A subtype, and equivalent affinity for the 5-HT2B receptor. 2 The selective 5-HT2C receptor antagonist SB242,084 (0.5 mg kg(-1) i.p.), blocked the hypoactivity and penile grooming induced by Ro60-0175 (1 mg kg(-1) s.c.). The combination of SB242,084 (0.5 mg kg(-1) i.p.) and Ro60-0175 (3-10 mg kg(-1)) produced a completely different pattern of behaviours including wet-dog shakes, hyperactivity and back muscle contractions. These latter effects were blocked by the selective 5-HT2A receptor antagonist MDL100,907 (0.5 mg kg (1) i.p.), but not the 5-HT2B receptor antagonist SB215,505 (3 mg kg (1) p.o.). 3 The indirect 5-HT releaser/reuptake inhibitor dexfenfluramine (1-10 mg kg (1) i.p.) produced a mild increase in locomotor activity, penile grooming, and occasional back muscle contractions and wet-dog shakes. Pre-treatment with SB242,084 (0.5 mg kg(-1)), blocked the incidence of penile grooming, and markedly potentiated both the dexfenfluramine-induced hyperactivity, the incidence of back muscle contractions, and to a lesser extent wet-dog shakes. Some toxicity was also evident in animals treated with dexfenfluramine (10 mg kg(-1))/SB242.084 (0.5 mg kg (1)), but not in any other treatment groups. 4 The hyperactivity and toxicity produced by the dexfenfluramine (10 mg kg(-1))/SB242,084 (0.5 mg kg(-1)) combination was replicated in a further study, and hyperthermia was also recorded. Both hyperthermia and toxicity were blocked by MDL100,907 (0.5 mg kg(-1)) but not SB215,505 (3 mg kg(-1)). An attenuation of the hyperlocomotor response was also observed following MDL100,907. 5 These findings suggest that 5-HT2C receptor activation can inhibit the expression of behaviours mediated through other 5-HT receptor subtypes.
引用
收藏
页码:459 / 466
页数:8
相关论文
共 35 条
[1]  
Aghajanian GK, 1999, NEUROPSYCHOPHARMACOL, V21, pS16
[2]   A review of central 5-HT receptors and their function [J].
Barnes, NM ;
Sharp, T .
NEUROPHARMACOLOGY, 1999, 38 (08) :1083-1152
[3]   5-HT2 RECEPTOR SUBTYPES - A FAMILY RE-UNITED [J].
BAXTER, G ;
KENNETT, G ;
BLANEY, F ;
BLACKBURN, T .
TRENDS IN PHARMACOLOGICAL SCIENCES, 1995, 16 (03) :105-110
[4]   BEHAVIORAL EVIDENCE FOR FUNCTIONAL INTERACTIONS BETWEEN 5-HT-RECEPTOR SUBTYPES IN RATS AND MICE [J].
BERENDSEN, HHG ;
BROEKKAMP, CLE .
BRITISH JOURNAL OF PHARMACOLOGY, 1990, 101 (03) :667-673
[5]   DRUG-INDUCED PENILE ERECTIONS IN RATS - INDICATIONS OF SEROTONIN1B RECEPTOR MEDIATION [J].
BERENDSEN, HHG ;
BROEKKAMP, CLE .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1987, 135 (03) :279-287
[6]   5-HT2C receptor modulation and the treatment of obesity [J].
Bickerdike, MJ ;
Vickers, SP ;
Dourish, CT .
DIABETES OBESITY & METABOLISM, 1999, 1 (04) :207-214
[7]   MOLECULAR-BIOLOGY OF 5-HT RECEPTORS [J].
BOESS, FG ;
MARTIN, IL .
NEUROPHARMACOLOGY, 1994, 33 (3-4) :275-317
[8]   6-chloro-5-methyl-1-[[2-[(2-methyl-3-pyridyl)oxy]-5-pyridyl]carbamoyl]-indoline (SB-242084): The first selective and brain penetrant 5-HT2C receptor antagonist [J].
Bromidge, SM ;
Duckworth, M ;
Forbes, IT ;
Ham, P ;
King, FD ;
Thewlis, KM ;
Blaney, FE ;
Naylor, CB ;
Blackburn, TP ;
Kennett, GA ;
Wood, MD ;
Clarke, SE .
JOURNAL OF MEDICINAL CHEMISTRY, 1997, 40 (22) :3494-3496
[9]   EVIDENCE THAT RU-24969-INDUCED LOCOMOTOR-ACTIVITY IN C57/B1/6 MICE IS SPECIFICALLY MEDIATED BY THE 5-HT(1B) RECEPTOR [J].
CHEETHAM, SC ;
HEAL, DJ .
BRITISH JOURNAL OF PHARMACOLOGY, 1993, 110 (04) :1621-1629
[10]   EVOLUTION OF A NOVEL SERIES OF [(N,N-DIMETHYLAMINO)PROPYL]ANILIDE AND PIPERAZINYLBENZANILIDES AS THE FIRST SELECTIVE 5-HT1D ANTAGONISTS [J].
CLITHEROW, JW ;
SCOPES, DIC ;
SKINGLE, M ;
JORDAN, CC ;
FENIUK, W ;
CAMPBELL, IB ;
CARTER, MC ;
COLLINGTON, EW ;
CONNOR, HE ;
HIGGINS, GA ;
BEATTIE, D ;
KELLY, HA ;
MITCHELL, WL ;
OXFORD, AW ;
WADSWORTH, AH ;
TYERS, MB .
JOURNAL OF MEDICINAL CHEMISTRY, 1994, 37 (15) :2253-2257